This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Winners & Losers: ImClone

Health stocks rebounded a bit from Monday's market mess on Tuesday, but slightly underperformed the broader markets.

After losing roughly 3% apiece on Monday, the Nasdaq and Amex biotechnology indices closed up 2.8% and 2.4%, respectively.

Big biotech Amgen regained 6.8%, while Celgene rebounded 13%.

Investors are waiting to hear from ImClone (IMCL) and its mystery flirtation as the deadline draws near for that $70-a-share bidder to make up its mind. The unknown pharmaceutical company will have to make a firm offer or withdraw its bid by midnight Wednesday. ImClone shares closed up 44 cents, or 0.7%, at $62.40.

Shares of Bristol-Myers Squibb (BMY), which last week announced a hostile tender for ImClone's shares at $62 a share, closed up $1, or 5.0%, at $20.85.

Pfizer (PFE) gave an update on its pipeline, saying that t now has 25 programs in late stage development - up from 16 six months ago. The company said the majority of advances have been in oncology, pain, inflammation, diabetes, Alzheimer's disease and schizophrenia. It is targeting between 15 and 20 regulatory submissions between 2010 and 2012.

The Wall Street Journal reported late Monday that Pfizer would not develop newer products for heart disease, obesity and bone health. Shares were up 79 cents, or 4.5%, at $18.44.

The publication also said that GlaxoSmithKline (GSK) may cut up to 850 more research and development jobs - about 6% of its total R&D staff. Shares of the pharmaceutical company were up $1.38, or 3.2%, at $43.46.

Brean Murray, Carret & Co analyst Jonathan Aschoff started coverage on Auxilium Pharmaceuticals (AUXL) with a sell rating and an $18 price target. Shares were down 60 cents, or 1.8%, at $32.40.

Also, Roth Capital initiated coverage on medical device company Synovis Life Technologies (SYNO) with a hold rating and a $21 price target. Shares were off by 20 cents, or 1.1%, at $18.82.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs